Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive single-molecule digital immunoassay for quantifying phosphorylated Tau at threonine 217 (p-Tau217) in plasma, serum, CSF, and brain tissue lysates down to sub-picogram per milliliter limits.
As the premier fluid biomarker of cerebral amyloid-beta plaque deposition and progressive neurofibrillary tangle pathology, blood p-Tau217 enables early asymptomatic stratification and longitudinal pharmacodynamic monitoring across preclinical Alzheimer's disease models. Creative Proteomics helps you build a fit-for-purpose study framework and delivers publication-ready concentration datasets.
Structuring sampling timelines, baseline normalization, and multi-marker panels for Alzheimer's pipelines.
Translating biofluid p-Tau217 measurements into actionable drug discovery decisions requires structuring the analytical plan around the progressive pathological cascade. Creative Proteomics establishes five universal design dimensions prior to testing:
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Pathological Staging Window | Pre-plaque baseline, early oligomeric seeding (Braak II), or overt plaque saturation (Braak IV+) | Captures early biomarker divergence before secondary structural neuroaxonal damage becomes irreversible. |
| Baseline & Vehicle Controls | Pre-treatment intra-individual baselines vs. age-matched parallel non-transgenic wild-type cohorts | Separates genuine therapeutic suppression of tau hyperphosphorylation from age-dependent baseline accumulation. |
| Multi-Marker Alignment | p-Tau217 as primary amyloid-tau endpoint + contextual markers (Simoa NfL for axonal loss, glial fibrillary acidic protein [GFAP] for astrogliosis) | Provides a comprehensive ATN (Amyloid, Tau, Neurodegeneration) profile from a single shared sample aliquot. |
| Analytical Volume Allocation | Serial micro-volume allocation (15 μL net), duplicate confirmation, and orthogonal follow-up reserve | Preserves longitudinal small-animal biofluids (e.g., serial submandibular bleeds) across multi-month regimens. |
| Plate Balancing & Randomization | Balancing vehicle, candidate drug doses, and longitudinal timepoints across analytical disc runs | Prevents confounding between experimental treatment effects and run-to-run bioanalytical variance. |
Evaluating analytical specificity, fold-induction, and translational biomarker performance across key tau phosphorylation residues.
| Biomarker Target | Pathology Correlation | Relative Fold-Change in Blood | Primary Preclinical Application |
|---|---|---|---|
| p-Tau217 (Our Primary Focus) | Direct surrogate of Aβ plaques & early tau tangles | 4.0–8.0× (Highest dynamic range) | Early AD cohort stratification, IND candidate screening, efficacy tracking |
| p-Tau181 | Intermediate amyloid-associated hyperphosphorylation | 1.5–3.0× | Broad cohort baseline profiling, legacy dataset alignment |
| p-Tau231 | Earliest conformational transition of tau monomer | 1.8–3.5× | Ultra-early pre-symptomatic threshold modeling |
| Total Tau (t-Tau) | Non-specific acute neuroaxonal structural release | 1.2–1.8× | Acute trauma, stroke, baseline total tau normalizer |
Evaluating analytical performance, multiplexing capacity, and data continuity across bioanalytical platforms for translational Alzheimer's programs.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | >10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.5 – 2.0 pg/mL | 0.00977 – 0.02 pg/mL (fg/mL level) |
| Healthy Blood Basal Detectability | Undetectable in blood | Undetectable in normal plasma | Partial (high elevated cases only) | 100% Quantifiable across all cohorts |
| Sample Volume Consumption | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Multiplex Capacity | Singleplex (1 analyte) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 plex) |
| Linear Dynamic Range | 2.0 logs | 3.0 – 3.5 logs | 3.5 – 4.0 logs | >4.5 logs (Poisson digital + Analog) |
| Small Rodent Serial Sampling | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial tail-vein / submandibular) |
| Primary Matrix Suitability | High-titer recombinant in vitro | Multiplex screening cohorts | CSF, brain tissue homogenates | Peripheral blood (serum/plasma), micro-fluids |
Cross-platform transitions from legacy ELISA, Lumipulse, MSD, Luminex, or immuno-affinity mass spectrometry (LC-MS/MS) require formal method bridging. Variations in antibody clone epitopes (e.g., ALZpath vs. Lilly IBA493), synthetic calibrator peptide purity, and matrix dilution factors commonly introduce proportional numerical shifts, even when inter-platform rank correlations exceed r = 0.95.
Our Bridging Protocol: We analyze a representative pilot subset (15–20 paired baseline and elevated research specimens) in parallel across both platforms to establish a validated linear conversion algorithm, ensuring dataset continuity across multi-year drug discovery campaigns.
Bioanalytical parameters validated according to FDA Bioanalytical Method Validation (BMV) and International Council for Harmonisation (ICH) M10 guidelines.
High-affinity monoclonal antibody pair specifically binds phosphorylated Thr217 while showing zero cross-reactivity with unphosphorylated tau or adjacent phosphorylation sites (p-Tau181, p-Tau231).
Validated quantitative correlation (r > 0.85, AUC 0.88–0.96) with cortical amyloid-beta plaque deposition and early Braak stage II neurofibrillary tangle seeding in translational cohorts.
Parallelism confirmed across 1:2 to 1:16 plasma dilutions with active heterophilic blockers, eliminating human anti-mouse antibody (HAMA) and rheumatoid factor interference.
Specimens received on dry ice are barcode-logged, assessed for hemolysis/lipemia, and cataloged into monitored −80 °C storage.
Automated liquid handling performs sample dilution in matrix-matched assay diluent supplemented with selective blockers (HAMA/HAAA).
Target p-Tau217 is captured onto paramagnetic beads functionalized with high-affinity anti-p-Tau217 monoclonal antibodies, followed by detector binding.
Bead-enzyme complexes (SBG) are loaded onto optical Simoa discs with 216,000 femtoliter wells, sealed with oil, and imaged for digital enzyme counting.
Average Enzymes per Bead (AEB) values are fitted against the calibration curve to output absolute pg/mL concentrations and QC statistics.
A standardized pre-analytical framework to preserve phospho-epitope integrity and prevent non-biological variance.
| Pre-Analytical Parameter | Why It Matters for p-Tau217 Quantification | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Phosphorylated epitopes are sensitive to matrix composition; K2-EDTA yields superior signal-to-noise ratios and stability over heparin. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted consistently for 30–60 min at RT. |
| Centrifugation Timing | Endogenous blood phosphatases can dephosphorylate Thr217 if whole blood remains uncentrifuged at room temperature. | Centrifuge at 2,000 μg for 15 min at 4 °C within 60 minutes of collection; harvest platelet-poor plasma. |
| Phosphatase Inhibition | Tissue homogenates contain active serine/threonine phosphatases that rapidly degrade p-Tau signals post-lysis. | Include broad-spectrum phosphatase inhibitors (1 mM Na3VO4, 50 mM NaF) in RIPA or Tris lysis buffers. |
| Freeze-Thaw Stability | p-Tau217 maintains high stability in EDTA plasma, but repeated freeze-thaw cycles (>4 cycles) can increase background. | Aliquot immediately into polypropylene cryovials; store at −80 °C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Micro-volume consumption allows serial longitudinal sampling in precious transgenic rodent cohorts. | 15 μL net volume per well (30 μL recommended to support duplicate verification and analytical reserve). |
| Run Allocation & Balancing | Placing baseline and post-treatment cohorts on separate plates risks confounding treatment effects with batch variance. | We pre-plan plate layouts so that paired longitudinal timepoints and cohort groups are balanced across the same run. |
Accelerating translational neuroscience, biomarker discovery, and drug candidate validation.
Monitor downstream reduction in blood p-Tau217 following amyloid plaque clearance in APP/PS1 and 5xFAD transgenic mouse models.
Identify incipient amyloid-positive pathology in asymptomatic transgenic cohorts prior to detectable amyloid-PET or cognitive decline.
Evaluate whether novel BACE1 inhibitors or gamma-secretase modulators successfully halt downstream cortical tau phosphorylation cascades.
Integrate blood p-Tau217 as the premier "T" (Tau) dimension alongside Simoa NfL ("N") and Aβ42/40 ("A").
Measure direct pharmacodynamic suppression of Thr217 hyperphosphorylation following CDK5 or GSK3β small-molecule inhibitor administration.
Convert and align preclinical biofluid datasets between MSD ECL and digital Simoa p-Tau217 platforms across multi-year drug discovery pipelines.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark peer-reviewed studies establishing p-Tau217 as the leading blood biomarker for Alzheimer's pathology.
Study Design Takeaway: Validates ALZpath Simoa p-Tau217 assay accuracy (AUC > 0.92) across multi-center cohorts, demonstrating equivalence to CSF biomarkers.
Study Design Takeaway: Demonstrates high specificity of p-Tau217 in differentiating AD from non-AD tauopathies and frontotemporal dementias.
Study Design Takeaway: Proves p-Tau217 has a significantly higher dynamic fold-induction and tighter correlation with early amyloid deposition than p-Tau181.
Study Design Takeaway: Highlights p-Tau217 as a quantitative pharmacodynamic endpoint for monitoring anti-amyloid and anti-tau therapeutic interventions.
Study Design Takeaway: Shows that longitudinal increase in plasma p-Tau217 accelerates selectively in amyloid-positive preclinical subjects.
Addressing common bioanalytical and project planning inquiries.
Cross-cohort benchmarking studies demonstrate that plasma p-Tau217 exhibits the largest dynamic fold-change increase (4- to 8-fold increase in amyloid-positive vs. negative cohorts) and achieves the highest overall accuracy (AUC > 0.95) for detecting cerebral amyloidosis. It correlates more strongly with longitudinal cognitive decline and Amyloid-PET progression than p-Tau181 or p-Tau231.
Cross-platform comparisons should be treated as a formal bridging exercise. While relative rankings and fold-changes correlate strongly (r > 0.95), absolute concentrations may show a systematic proportional shift due to differences in calibrator peptide formulation and antibody avidity. We test a subset of bridging samples to establish a mathematical conversion factor.
K2-EDTA plasma is strongly recommended for longitudinal animal studies due to high stability and lower pre-analytical variability. Serum is also fully compatible when processed under uniform 30–60 min clotting SOPs. We recommend maintaining the same collection tube type across all longitudinal study timepoints.
Phosphorylated tau epitopes are susceptible to endogenous phosphatase activity if whole blood remains uncentrifuged at room temperature. We recommend centrifuging blood within 60 minutes of collection at 4 °C and storing plasma aliquots at −80 °C. For tissue homogenates, include a cocktail of broad-spectrum serine/threonine phosphatase inhibitors (1 mM Na3VO4, 50 mM NaF).
Yes. The amino acid sequence surrounding tau Thr217 is conserved in non-human primates (Cynomolgus and Rhesus macaques). In rodent studies, the assay robustly quantifies human p-Tau217 expressed in humanized and transgenic AD mouse models (such as APP/PS1, 5xFAD, 3xTg-AD, and Tau P301S lines).
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×